tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH), Prometheus Biosciences (RXDX) and Adverum Biotechnologies (ADVM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cardinal Health (CAHResearch Report), Prometheus Biosciences (RXDXResearch Report) and Adverum Biotechnologies (ADVMResearch Report).

Cardinal Health (CAH)

In a report released today, A.J. Rice from Credit Suisse maintained a Hold rating on Cardinal Health, with a price target of $64.00. The company’s shares closed last Friday at $69.41.

According to TipRanks.com, Rice is a 5-star analyst with an average return of 11.5% and a 62.6% success rate. Rice covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Privia Health Group, and Patterson Companies.

The word on The Street in general, suggests a Hold analyst consensus rating for Cardinal Health with a $65.00 average price target, representing a -1.2% downside. In a report released yesterday, Robert W. Baird also maintained a Hold rating on the stock with a $73.00 price target.

See the top stocks recommended by analysts >>

Prometheus Biosciences (RXDX)

Credit Suisse analyst Tiago Fauth maintained a Buy rating on Prometheus Biosciences today and set a price target of $59.00. The company’s shares closed last Friday at $49.36, close to its 52-week high of $51.96.

According to TipRanks.com, Fauth ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.3% and a 36.6% success rate. Fauth covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Apellis Pharmaceuticals, and United Therapeutics.

Prometheus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $55.22, an 8.3% upside from current levels. In a report released today, SVB Securities also maintained a Buy rating on the stock with a $60.00 price target.

Adverum Biotechnologies (ADVM)

In a report released today, Daniil Gataulin from Chardan Capital maintained a Hold rating on Adverum Biotechnologies, with a price target of $2.50. The company’s shares closed last Friday at $1.47.

According to TipRanks.com, Gataulin is a 2-star analyst with an average return of 1.0% and a 42.9% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, EyePoint Pharmaceuticals, and Oyster Point Pharma.

Currently, the analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $3.25, implying a 105.7% upside from current levels. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $5.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CAH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More